Selected research
Industry Research
Medical Blood Products Industry Research Report 2026
Market perspective
The global Medical Blood Products market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Medical Blood Products is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Medical Blood Products is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Medical Blood Products is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Medical Blood Products include Beijing Tiantan Biological Products, China Biologic Products Holdings, RAAS, HUALAN BIOLOGICAL ENGINEERING, China Resources Boya Bio-pharmaceutical Group, Takeda, Octapharma, LFB Group and Kedrion, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Medical Blood Products market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Medical Blood Products Market by Company
Beijing Tiantan Biological Products
China Biologic Products Holdings
RAAS
HUALAN BIOLOGICAL ENGINEERING
China Resources Boya Bio-pharmaceutical Group
Takeda
Octapharma
LFB Group
Kedrion
Grifols
CSL
BPL
Biotest
Medical Blood Products Segment by Type
Protein Products
Coagulation Factor Products
Other Blood Products
Whole Blood And Blood Components
Plasma Products
Medical Blood Products Segment by Application
Hospital
Clinic
Medical Blood Products Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medical Blood Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medical Blood Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medical Blood Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Medical Blood Products manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Medical Blood Products by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Medical Blood Products in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Protein Products
- Coagulation Factor Products
- Other Blood Products
- Whole Blood And Blood Components
- Plasma Products
Applications
- Hospital
- Clinic
Companies covered
- Beijing Tiantan Biological Products
- China Biologic Products Holdings
- RAAS
- HUALAN BIOLOGICAL ENGINEERING
- China Resources Boya Bio-pharmaceutical Group
- Takeda
- Octapharma
- LFB Group
- Kedrion
- Grifols
- CSL
- BPL
- Biotest
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Medical Blood Products Market Size (2021-2032)
- 2.2.2 Global Medical Blood Products Sales (2021-2032)
- 2.2.3 Global Medical Blood Products Market Average Price (2021-2032)
- 2.3 Medical Blood Products by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Protein Products
- 2.3.3 Coagulation Factor Products
- 2.3.4 Other Blood Products
- 2.3.5 Whole Blood And Blood Components
- 2.3.6 Plasma Products
- 2.4 Medical Blood Products by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Medical Blood Products Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Medical Blood Products Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Medical Blood Products Revenue of Manufacturers (2021-2026)
- 3.4 Global Medical Blood Products Average Price by Manufacturers (2021-2026)
- 3.5 Global Medical Blood Products Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Medical Blood Products, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Medical Blood Products, Product Type & Application
- 3.8 Global Manufacturers of Medical Blood Products, Established Date
- 3.9 Global Medical Blood Products Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Beijing Tiantan Biological Products
- 4.1.1 Beijing Tiantan Biological Products Company Information
- 4.1.2 Beijing Tiantan Biological Products Business Overview
- 4.1.3 Beijing Tiantan Biological Products Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Beijing Tiantan Biological Products Medical Blood Products Product Portfolio
- 4.1.5 Beijing Tiantan Biological Products Recent Developments
- 4.2 China Biologic Products Holdings
- 4.2.1 China Biologic Products Holdings Company Information
- 4.2.2 China Biologic Products Holdings Business Overview
- 4.2.3 China Biologic Products Holdings Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 China Biologic Products Holdings Medical Blood Products Product Portfolio
- 4.2.5 China Biologic Products Holdings Recent Developments
- 4.3 RAAS
- 4.3.1 RAAS Company Information
- 4.3.2 RAAS Business Overview
- 4.3.3 RAAS Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 RAAS Medical Blood Products Product Portfolio
- 4.3.5 RAAS Recent Developments
- 4.4 HUALAN BIOLOGICAL ENGINEERING
- 4.4.1 HUALAN BIOLOGICAL ENGINEERING Company Information
- 4.4.2 HUALAN BIOLOGICAL ENGINEERING Business Overview
- 4.4.3 HUALAN BIOLOGICAL ENGINEERING Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 HUALAN BIOLOGICAL ENGINEERING Medical Blood Products Product Portfolio
- 4.4.5 HUALAN BIOLOGICAL ENGINEERING Recent Developments
- 4.5 China Resources Boya Bio-pharmaceutical Group
- 4.5.1 China Resources Boya Bio-pharmaceutical Group Company Information
- 4.5.2 China Resources Boya Bio-pharmaceutical Group Business Overview
- 4.5.3 China Resources Boya Bio-pharmaceutical Group Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 China Resources Boya Bio-pharmaceutical Group Medical Blood Products Product Portfolio
- 4.5.5 China Resources Boya Bio-pharmaceutical Group Recent Developments
- 4.6 Takeda
- 4.6.1 Takeda Company Information
- 4.6.2 Takeda Business Overview
- 4.6.3 Takeda Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Takeda Medical Blood Products Product Portfolio
- 4.6.5 Takeda Recent Developments
- 4.7 Octapharma
- 4.7.1 Octapharma Company Information
- 4.7.2 Octapharma Business Overview
- 4.7.3 Octapharma Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Octapharma Medical Blood Products Product Portfolio
- 4.7.5 Octapharma Recent Developments
- 4.8 LFB Group
- 4.8.1 LFB Group Company Information
- 4.8.2 LFB Group Business Overview
- 4.8.3 LFB Group Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 LFB Group Medical Blood Products Product Portfolio
- 4.8.5 LFB Group Recent Developments
- 4.9 Kedrion
- 4.9.1 Kedrion Company Information
- 4.9.2 Kedrion Business Overview
- 4.9.3 Kedrion Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Kedrion Medical Blood Products Product Portfolio
- 4.9.5 Kedrion Recent Developments
- 4.10 Grifols
- 4.10.1 Grifols Company Information
- 4.10.2 Grifols Business Overview
- 4.10.3 Grifols Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Grifols Medical Blood Products Product Portfolio
- 4.10.5 Grifols Recent Developments
- 4.11 CSL
- 4.11.1 CSL Company Information
- 4.11.2 CSL Business Overview
- 4.11.3 CSL Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 CSL Medical Blood Products Product Portfolio
- 4.11.5 CSL Recent Developments
- 4.12 BPL
- 4.12.1 BPL Company Information
- 4.12.2 BPL Business Overview
- 4.12.3 BPL Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 BPL Medical Blood Products Product Portfolio
- 4.12.5 BPL Recent Developments
- 4.13 Biotest
- 4.13.1 Biotest Company Information
- 4.13.2 Biotest Business Overview
- 4.13.3 Biotest Medical Blood Products Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Biotest Medical Blood Products Product Portfolio
- 4.13.5 Biotest Recent Developments
5 Global Medical Blood Products Market Scenario by Region
- 5.1 Global Medical Blood Products Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Medical Blood Products Sales by Region: 2021-2032
- 5.2.1 Global Medical Blood Products Sales by Region: 2021-2026
- 5.2.2 Global Medical Blood Products Sales by Region: 2027-2032
- 5.3 Global Medical Blood Products Revenue by Region: 2021-2032
- 5.3.1 Global Medical Blood Products Revenue by Region: 2021-2026
- 5.3.2 Global Medical Blood Products Revenue by Region: 2027-2032
- 5.4 North America Medical Blood Products Market Facts & Figures by Country
- 5.4.1 North America Medical Blood Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Medical Blood Products Sales by Country (2021-2032)
- 5.4.3 North America Medical Blood Products Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Medical Blood Products Market Facts & Figures by Country
- 5.5.1 Europe Medical Blood Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Medical Blood Products Sales by Country (2021-2032)
- 5.5.3 Europe Medical Blood Products Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Medical Blood Products Market Facts & Figures by Country
- 5.6.1 Asia Pacific Medical Blood Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Medical Blood Products Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Medical Blood Products Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Medical Blood Products Market Facts & Figures by Country
- 5.7.1 South America Medical Blood Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Medical Blood Products Sales by Country (2021-2032)
- 5.7.3 South America Medical Blood Products Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Medical Blood Products Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Medical Blood Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Medical Blood Products Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Medical Blood Products Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Medical Blood Products Sales by Type (2021-2032)
- 6.1.1 Global Medical Blood Products Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Medical Blood Products Sales Market Share by Type (2021-2032)
- 6.2 Global Medical Blood Products Revenue by Type (2021-2032)
- 6.2.1 Global Medical Blood Products Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Medical Blood Products Revenue Market Share by Type (2021-2032)
- 6.3 Global Medical Blood Products Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Medical Blood Products Sales by Application (2021-2032)
- 7.1.1 Global Medical Blood Products Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Medical Blood Products Sales Market Share by Application (2021-2032)
- 7.2 Global Medical Blood Products Revenue by Application (2021-2032)
- 7.2.1 Global Medical Blood Products Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Medical Blood Products Revenue Market Share by Application (2021-2032)
- 7.3 Global Medical Blood Products Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Medical Blood Products Value Chain Analysis
- 8.1.1 Medical Blood Products Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Medical Blood Products Production Mode & Process
- 8.2 Medical Blood Products Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Medical Blood Products Distributors
- 8.2.3 Medical Blood Products Customers
9 Global Medical Blood Products Analyzing Market Dynamics
- 9.1 Medical Blood Products Industry Trends
- 9.2 Medical Blood Products Industry Drivers
- 9.3 Medical Blood Products Industry Opportunities and Challenges
- 9.4 Medical Blood Products Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst